Abstract | PURPOSE: MATERIALS AND METHODS: Previously untreated 20 patients with locally advanced HNSCC (Oral cavity/oropharynx/larynx/hypopharynx) were treated with definitive hypofractionated radiotherapy of 60Gy in 25 fractions with concurrent cisplatin @35 mg/m2 once weekly for 5 weeks from March 2020 to November 2021. The patients were treated on 6MV LINAC with Volumetric modulated arc therapy (VMAT) by the Sequential boost technique and concurrent chemotherapy @35 mg/m2. All the patients received 48Gy in 20 fractions to low-risk volume (CTV LR) in Phase I followed by 12Gy in 5 fractions boost to High-risk volume (CTV HR) in Phase II. The organs at risk (OARs) were contoured and appropriate constraints were given considering the hypofractionated regimen. RESULTS: Out of 20 patients, most of the patients were Stage IV (15;75%) & stage III 20%, out of which (55%) 11 were of the oral cavity, (40%) 8 were of the oropharynx, and (5%) 1 of larynx. All patients were treated with 60Gy/25#/5 weeks with the majority of the patients (17;85%) completing their treatment in less than 45 days. The Median follow-up was of 214 days. The locoregional control at 6 Months was 55%. Maximum acute toxicity was grade 3 mucositis which was observed in 18 (90%) patients. Ryle's tube feeding was needed in 11 (55%) patient. Out of 20 patients, 5 patients did not receive concurrent chemotherapy, and 8 (40%) patients received all 5 cycles of chemotherapy. 7, 35% of the patients could not complete all 5 cycles of concurrent chemotherapy due to grade 3 mucositis. CONCLUSION: During a pandemic crisis with limited manpower & technical resources accelerated hypofractionated radiotherapy with concurrent chemotherapy can be considered a feasible therapeutic option for HNSCC which can significantly reduce the overall Treatment Time (OTT) with comparable local control and manageable toxicities.
|
Authors | Sumit Agarwal, Isha Jaiswal, Uday P Shahi, Abhijit Mandal, Lalit M Aggarwal, Ankita Singh, Anil Jaiswal, Nandlal Yadawa |
Journal | Journal of cancer research and therapeutics
(J Cancer Res Ther)
Vol. 20
Issue 1
Pg. 404-409
(Jan 01 2024)
ISSN: 1998-4138 [Electronic] India |
PMID | 38554353
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics. |
Chemical References |
|
Topics |
- Humans
- Squamous Cell Carcinoma of Head and Neck
(drug therapy)
- Mucositis
(epidemiology, etiology)
- Tertiary Healthcare
- Carcinoma, Squamous Cell
(radiotherapy)
- COVID-19
- Head and Neck Neoplasms
(radiotherapy)
- Cisplatin
|